RT Journal Article
SR Electronic
T1 A mHealth intervention (mTB-Tobacco) for smoking cessation in people with drug-sensitive pulmonary tuberculosis: protocol for an adaptive design, cluster randomised controlled trial (Quit4TB)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.10.24318761
DO 10.1101/2024.12.10.24318761
A1 Zahid, Maham
A1 Rahman, Fahmidur
A1 Lim, Ai Keow
A1 Chowdhury, Asiful
A1 Rana, Shakhawat Hossain
A1 Ansari, Saeed
A1 Danaee, Mahmoud
A1 Boeckmann, Melanie
A1 Parrott, Steve
A1 Norrie, John
A1 Khan, Amina
A1 Huque, Rumana
A1 Siddiqi, Kamran
A1 the RESPIRE collaboration
YR 2024
UL http://medrxiv.org/content/early/2024/12/10/2024.12.10.24318761.abstract
AB Introduction People with tuberculosis (TB) who continue to smoke are more likely to have poor health outcomes than those who quit. Established smoking cessation approaches such as mHealth may help TB patients quit smoking. This paper summarises the methodology proposed to assess the effectiveness and cost-effectiveness of mTB-Tobacco (an mHealth intervention) in helping TB patients stop smoking and have improved health outcomes.Methods and analysis A two-arm, parallel, open-label, multi-centre, cluster randomised, two-stage adaptive design trial is proposed to first evaluate the superiority of mTB-Tobacco, compared with usual care and then the non-inferiority of mTB-tobacco compared with face-to-face behaviour support. Study settings include TB treatment centres in Bangladesh and Pakistan. The study population includes adult patients, newly diagnosed (within four weeks) with pulmonary TB disease, daily smokers, willing to quit, and have access to mobile phones. The primary outcome includes biochemically verified continuous smoking abstinence assessed at 6 months per Russell Standard. A generalised linear mixed-effects model will be used to assess the impact of mTB-Tobacco intervention on continuous outcomes, incorporating fixed effects for the intervention, random effects for clusters, and relevant covariates. Cost-effectiveness analysis will be done to estimate the cost per quitter and cost per QALY gained, calculate the incremental cost-effectiveness ratios (ICER) to establish the value for money for mTB-Tobacco.Ethics and dissemination This trial will be conducted in compliance with ICH-GCP guidelines and the Declaration of Helsinki. The study has been approved by the ethics committees of the University of Edinburgh Medical School Research Ethics Committee (EMREC) of UK, the Bangladesh Medical Research Council (BMRC) and the National Bioethics Committee (PMRC) of Pakistan.Funding The study is funded by the National Institute of Health Research (NIHR) UK under a research award named NIHR Global Health Research Unit on Respiratory Health (RESPIRE) (Award ID: NIHR132826)Trial registration number ISRCTN86971818 (https://doi.org/10.1186/ISRCTN86971818); Submission date:29/08/2023; Registration date:11/09/2023; Last edited:30/04/2024Strengths and limitations of this studyThis trial will be the first one to test the effectiveness of mHealth based intervention to help TB patients quit smoking at 6 months.An effective mTB-Tobacco intervention could be transformational for TB patients who smoke. It will not only benefit the TB patients but will also allow the national TB control programmes to have a less resource-intensive and effective intervention for smoking cessation that can be easily integrated into their system.The web portal that will be developed under this project can be used by TB programmes with no to minimal extra cost to only account for the SMS text message delivery.TB disease is more prevalent in vulnerable populations e.g. lower socioeconomic groups, and such population is more likely to have poor literacy as compared to the general population. This can be a challenge as TB patients’ ability to read and understand SMS messages may be a barrier.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN86971818Funding StatementThe study is funded by the National Institute of Health Research (NIHR) UK under a research award named NIHR Global Health Research Unit on Respiratory Health (RESPIRE) (Award ID: NIHR132826)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Bioethics Committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors